Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : New technology that screws up other new technology -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4)	1/10/1999 10:42:00 PM
From: David S.	Respond to of 20

One reason consumers may not switch from A to B is that they might not know that "B" exists. Regarding Viracept, another "gentleman" (I use the term loosely) was making blatantly false claims about protease inhibitors and was neglecting to mention minor things about Agouron such as: FDA warning and the company's run in with the University of California regarding experimental data that magically was transported in Star Trek fashion from UC labs to that of Agouron. The issue of longevity of Viracept is one of the shape of the growth and decline curve.